Brett Welch

Brett Welch Email and Phone Number

⇨PHARMACEUTICAL R&D⇦ | Drug Discovery | Preclinical Development | Technology & Strategy | Fundraising | Regulatory @ ACELYRIN, INC.
Brett Welch's Location
Salt Lake City, Utah, United States, United States
Brett Welch's Contact Details

Brett Welch personal email

About Brett Welch

I am a passionate innovator and PHARMACEUTICAL SCIENTIST with over 20 years of experience discovering and advancing drug candidates from initial discovery through phase I clinical trials. I currently direct the technical aspects including manufacturing of multiple companion diagnostic (CDx) assays including the first approved CDx for certain gene replacement therapy patients. I HAVE:★ Co-authored and served as the principal investigator or key personnel on many NIH funded grants totaling $20M.★ Co-discovered lead candidate therapeutics for HIV, RSV, antibiotic-resistant bacterial infections, cancer, and inflammatory bowel disease.★ Set up new labs and automation systems.★ Negotiated exclusive licensing for novel pharmaceutical technologies.★ Prepared patent filings.★ Pitched to venture capital firms and large pharma executives.★ Led a successful investigational new drug (IND) application and several pre-IND applications.★ Participated in clinical operations for a promising clinical candidate.★ Helped establish and run a CLIA-regulated laboratory performing COVID-19 diagnostic testing.★ Directed technical operations of a high-risk medical device leading to the first regulatory approval for a companion diagnostic for gene replacement therapy.I EXCEL AT: ✔ Using business acumen, project management skills, and excellent communication abilities to build viable product profiles and advance scientific discovery.✔ Maintaining compliance with industry/government ethical and legal guidelines, standards, and regulations.✔ Working collaboratively across science and business to align teams with corporate mission and objectives.PERSONALITY TRAITS:✸ Analytical: I find connections between seemingly unrelated variables.✸ Innovative: I excel at developing long-term plans that meet ambitious business objectives.✸ Efficient: I strive to always find more efficient ways to do business.✸ Objective: I do not allow my ego to get in the way of progress and change.✸ Strategic: I am able to accomplish short-term goals without losing sight of the mission.

Brett Welch's Current Company Details
ACELYRIN, INC.

Acelyrin, Inc.

View
⇨PHARMACEUTICAL R&D⇦ | Drug Discovery | Preclinical Development | Technology & Strategy | Fundraising | Regulatory
Brett Welch Work Experience Details
  • Acelyrin, Inc.
    Sr. Director, Preclinical Pharmacology
    Acelyrin, Inc. Aug 2023 - Present
    Agoura Hills, California, Us
    Serve on the translational biology team and work with senior management to advance preclinical development and lifecycle management activities of current and potential new portfolio assets.
  • Arup Laboratories
    Director, Companion Diagnostic Technical Operations
    Arup Laboratories Sep 2021 - Aug 2023
    Salt Lake City, Utah, Us
    Was responsible for management and successful development, validation, process improvement, and manufacturing activities for multiple companion diagnostic (CDx) assay programs within the PharmaDx department. Served in this capacity for the two years leading up to a world-first FDA approval for a CDx assay supporting a gene-replacement therapy. This CDx was also the third medical device approved by the European Union under the IVDR standard.• Lead scientific and technical activities within the department• Mentored and managed 11 team members• Collaborated and partnered with multidisciplinary internal and external stakeholders • Provided regular updates to external sponsors’ senior leadership• Strategic analysis of critical programs • Proposal and budget review
  • Dbiotherapeutics
    Co-Founder And Cso
    Dbiotherapeutics Dec 2020 - Aug 2023
    Co-founded DBiotherapeutics to develop a novel anti-TNF therapeutic I co-discovered. Played a major role in:• Licensing the compound • Securing IP protection• Fundraising, including technology pitches to potential investors and drafting three awarded SBIR grants• Leading the company’s scientific activities and operations
  • Arch Biosolutions
    Principal Consultant
    Arch Biosolutions Mar 2020 - Aug 2023
    Consulted with pharmaceutical and diagnostic companies to shepherd drug candidates and diagnostic tools through R&D and regulatory approval.• Drafted and assembled the pre-IND briefing book for a novel cancer immunotherapy.• General supervisor of COVID-19 diagnostic laboratory. Designed and implemented scalable, semi- automated, CLIA-regulated workflows.• Advised on grant funding and development and regulatory strategies.
  • University Of Utah School Of Medicine
    Adjunct Professor Of Biochemistry
    University Of Utah School Of Medicine Feb 2016 - Mar 2023
    Salt Lake City, Ut, Us
  • Navigen, Inc.
    Consultant
    Navigen, Inc. Apr 2020 - Dec 2022
    Salt Lake City, Ut, Us
    • Served on the sponsor's clinical study monitoring team (unblinded contact). • Advised on multiple aspects of study design and execution including CMC, bioanalytical, and immunogenicity report review. • Authored sections of IND annual reports.
  • Navigen, Inc.
    Sr. Director, Technology And Strategy
    Navigen, Inc. Sep 2019 - Mar 2020
    Salt Lake City, Ut, Us
    Promoted to work directly with CEO to improve operational efficiency and identify/execute business development and Series A fundraising strategies for drug discovery and development company delivering innovative D-peptide therapeutics. Assisted in promoting technology and intellectual property (IP) portfolio to venture capital firms and private investors, attended investor conferences and scientific meetings, and supported patent filings.Tactical Accomplishments• Increased efficiency 10-fold by envisioning, integrating, and optimizing automation solutions for high-throughput drug-screening technology.• Led team in discovering differentiated drug candidate more potent than top-selling US pharmaceutical in fewer than 12 weeks.• Awarded $3M NIH grant to fund first-in-human clinical studies for the co-invented HIV inhibitor with personally co-designed clinical protocols; expected to play key role in future clinical operations.• Pitched technology to dozens of venture capital and big pharma executives.• Served as primary scientific contact for R&D portfolio of seven complex business development projects. Strategic Accomplishments• Synthesized perspectives, insights, and results to identify future market opportunities and reviewed external opportunities for potential acquisition and partnering.• Conducted market research and created brand story/presentation collateral to differentiate products.• Provided thorough scientific debriefs and industry insights to board.
  • Navigen, Inc.
    Senior Director, Research And Development
    Navigen, Inc. Apr 2018 - Sep 2019
    Salt Lake City, Ut, Us
    Promoted as part of leadership team charged with executing significant shift in corporate strategy, transitioning company from multiple technologies to an exclusive focus on D-peptide drug discovery and development. Grew team and platform, set scientific and operational standard operating procedures (SOPs), and directed research.• Achieved FDA clearance for novel HIV therapeutic candidate with first-in-human clinical trials in Q3 2020.• Served as primary regulatory scientist, author, and project manager for preclinical development and preparation of investigational new drug (IND) application.• Awarded $300K NIH grant and led research as primary investigator to discover a unique anti-TNF inhibitor for treatment of Crohn’s Disease and ulcerative colitis.• Reduced time required to identify lead candidates 75% by designing streamlined workflows and improving internal collaborative processes.• Leveraged strong leadership skills and proven ability to inspire collaboration to manage 15-member, multidisciplinary research team; wrote job descriptions, hired, trained, and supervised staff.
  • Navigen, Inc.
    Director & Lead Scientist, D-Peptide Research Division
    Navigen, Inc. Sep 2011 - Apr 2018
    Salt Lake City, Ut, Us
    Transitioned Kayak Bioscience’s nascent technology to an established company. Worked with a small team to actualize real-world treatment applications. Implemented best practice lab processes.• Co-discovered promising D-peptide inhibitors of RSV, Ebola virus, and shiga-toxin-producing E. coli currently in preclinical development.• Authored/co-authored, received funding, and served as principal investigator (six) or key personnel (four) on 10 NIH grants totaling $16.7M. • Negotiated with board and navigated internal politics to advance multiple, often complex, and sometimes competing, objectives and priorities to effective conclusion.• Conducted peer-level scientific discussions with key opinion leaders, provided in-depth scientific support to academic collaborators, and partnered with external contract research organizations (CROs). • Drafted provisional patent applications for several discovered assets.
  • Howard Hughes Medical Institute / Northwestern University
    Postdoc
    Howard Hughes Medical Institute / Northwestern University Apr 2008 - Sep 2011
    Chevy Chase, Maryland, Us
    • Developed novel model of early steps of paramyxovirus fusion with target cells.• Visiting scientist to University of Chicago and Stanford University to advance collaborative projects.
  • Sandbox Industries
    Visiting Fellow
    Sandbox Industries Jan 2010 - May 2011
    Chicago, Illinois, Us
    • Networked with investors; pitched proprietary technology to leadership at venture capital firms.
  • Kayak Biosciences
    Co-Founder
    Kayak Biosciences Sep 2009 - May 2011
    Assisted in pitching to investors for startup aiming to develop and commercialize HIV inhibitor co-discovered as a Ph.D. candidate. • Performed due diligence on outbound licensing and business development opportunities and negotiated $300K, 60% ownership deal with Navigen, Inc.

Brett Welch Skills

Biochemistry Protein Expression Molecular Biology Molecular Cloning Protein Chemistry Cell Culture Cell Biology Protein Purification Western Blotting Research Pcr Mutagenesis Life Sciences Structural Biology Drug Discovery Cell Genetics Virology Drug Design Drug Development Grant Writing Phage Display

Brett Welch Education Details

  • Northwestern University - Kellogg School Of Management
    Northwestern University - Kellogg School Of Management
    Business Administration And Management
  • University Of Utah
    University Of Utah
    Biochemistry
  • University Of Utah
    University Of Utah
    Chemistry And Biology

Frequently Asked Questions about Brett Welch

What company does Brett Welch work for?

Brett Welch works for Acelyrin, Inc.

What is Brett Welch's role at the current company?

Brett Welch's current role is ⇨PHARMACEUTICAL R&D⇦ | Drug Discovery | Preclinical Development | Technology & Strategy | Fundraising | Regulatory.

What is Brett Welch's email address?

Brett Welch's email address is we****@****ail.com

What schools did Brett Welch attend?

Brett Welch attended Northwestern University - Kellogg School Of Management, University Of Utah, University Of Utah.

What are some of Brett Welch's interests?

Brett Welch has interest in Soccer, Biking, Running, Home Remodeling, My Family, Mtn.

What skills is Brett Welch known for?

Brett Welch has skills like Biochemistry, Protein Expression, Molecular Biology, Molecular Cloning, Protein Chemistry, Cell Culture, Cell Biology, Protein Purification, Western Blotting, Research, Pcr, Mutagenesis.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.